APA

Favaloro L., Diez M., Mendiz O., Janavel G. V., Valdivieso L., Ratto R., Garelli G., Salmo F., Criscuolo M., Bercovich A. & Crottogini A. (20160511). High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial. : Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Chicago

Favaloro Liliana, Diez Mirta, Mendiz Oscar, Janavel Gustavo Vera, Valdivieso León, Ratto Roxana, Garelli Guillermo, Salmo Fabián, Criscuolo Marcelo, Bercovich Andrés and Crottogini Alberto. 20160511. High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial. : Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Harvard

Favaloro L., Diez M., Mendiz O., Janavel G. V., Valdivieso L., Ratto R., Garelli G., Salmo F., Criscuolo M., Bercovich A. and Crottogini A. (20160511). High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial. : Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

MLA

Favaloro Liliana, Diez Mirta, Mendiz Oscar, Janavel Gustavo Vera, Valdivieso León, Ratto Roxana, Garelli Guillermo, Salmo Fabián, Criscuolo Marcelo, Bercovich Andrés and Crottogini Alberto. High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial. : Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 20160511.